SMO and skin basal cell carcinoma: Moreover, treatment of MB or basal cell carcinoma (BCC), another Hh pathway-driven cancer, with these inhibitors causes gene mutations, including SMO and its downstream molecules, in tumor cells, which results in drug resistance [48–51].